Lung Cancer News From Medical News Today
Latest Lung Cancer News From Medical News Today.
- Last build:
- Language:
- en-us
- Feed URL:
- http://www.medicalnewstoday.com/rss/lung_cancer.xml
RSS FEED IDEMS: Lung Cancer News From Medical News Today
- Antisoma Announces Start Of Phase III Lung Cancer Trial Of ASA404
Cancer drug developer Antisoma plc (LSE: ASM; US OTC: ATSMY) announces that its partner Novartis has started the pivotal phase III trial of ASA404 combined with first-line chemotherapy in non-small cell lung cancer (NSCLC). The study, called ATTRACT-1, is designed to support applications for marketing authorisations in the US, Europe and other territories. Its initiation triggers a USD 25 million milestone payment to Antisoma.
Mon, 14 Apr 2008 05:00:00 PDT - Amrubicin Is Designated As An Orphan Medicinal Product By The European Commission For The Treatment Of Small Cell Lung Cancer
Celgene International Sarl (NASDAQ: CELG) announced that amrubicin hydrochloride has been designated as an orphan medicinal product by the European Commission (EC) for the treatment of small cell lung cancer following the favorable opinion of the European Medicines Agency's (EMEA) Committee for Orphan Medicinal Products (COMP).
Mon, 14 Apr 2008 03:00:00 PDT - ASA404, A Novel Cancer Agent, Begins Pivotal Trial To Explore New Approach In Treating Lung Cancer, The Leading Cause Of Cancer Death
Novartis announced that ASA404, its novel cancer agent, has entered a Phase III lung cancer trial following positive outcomes of a Phase II trial. The novel mechanism of action of ASA404 may represent a new approach to treating the most prevalent cause of cancer death. ASA404 is a Tumor-Vascular Disrupting Agent (Tumor-VDA) that selectively causes the collapse of existing tumor blood supply leading to extensive tumor cell death.
Mon, 14 Apr 2008 01:00:00 PDT - European Medicines Agency (EMEA) Approves ALIMTA® (pemetrexed For Injection) For Use In Lung Cancer Treatment
OnApril 11, 2008, an announcement by Eli Lilly and Company (NYSE:LLY) indicated that European health authorities have approved theuse of ALIMTA® (pemetrexed for injection) for a histologically-baseduse in the first-line treatment of advanced non-small-cell lung cancer(NSCLC), the most common form of lung cancer.
Mon, 14 Apr 2008 00:00:00 PDT - Biomoda To Present Paper On Enhanced Technology For Early Detection Of Lung Cancer At Annual SWARM Meeting
Researchers and executives from Biomoda, Inc. (OTC Bulletin Board: BMOD) (http://www.biomoda.
Fri, 11 Apr 2008 00:00:00 PDT - High-Intensity Chemotherapy Does Not Improve Survival In Small Cell Lung Cancer
Small cell lung cancer (SCLC) patients treated with high-dose chemotherapy did not have better survival rates than those treated with standard doses, according to a randomized controlled trial published online April 8 in the Journal of the National Cancer Institute.SCLC accounts for nearly 13 percent of lung cancer cases in the United States. Although many patients with SCLC initially respond to chemotherapy, most suffer disease recurrence relatively quickly.
Wed, 09 Apr 2008 05:00:00 PDT - Large International Study Identifies Genetic Predisposition To Lung Cancer
In a paper published in the April 3 edition of Nature*, a worldwide consortium of investigators present a major breakthrough for understanding the genetic basis of lung cancer. The international team of investigators have uncovered for the first time an important genetic region that is associated with lung cancer risk and helps to understand the process by which tobacco smoking can cause this cancer.
Fri, 04 Apr 2008 03:00:00 PDT - Genetic Variations Raise Lung Cancer Risk For Smokers And Ex Smokers
Two common inherited genetic variations are associated with increased risk of lung cancer for smokers and former smokers, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reports April 2 in the online edition of Nature Genetics."This is the first study to identify a common genetic variant that influences the risk for developing lung cancer," said lead author Chris Amos, Ph.D., professor in M. D.
Fri, 04 Apr 2008 00:00:00 PDT - Gene Linked To Lung Cancer Identified By Researchers
Researchers at Johns Hopkins, as part of a large, multi-institutional study, have found one gene variant that is linked to an increased risk of lung cancer. The study will be published in the April 3 issue of Nature Genetics.The research team collected DNA from 1,154 smokers who have lung cancer and 1,137 smokers without lung cancer.
Thu, 03 Apr 2008 03:00:00 PDT - New Method To Test For Lung Cancer Developed By Researchers
Researchers from Boston University School of Medicine have developed a new "clinicogenomic model" to accurately test for lung cancer. The model combines a specific gene expression for lung cancer as well as clinical risk factors. These findings currently appear on-line in the journal Cancer Prevention Research.Lung cancer is the leading cause of cancer death in the United States and the world, with more than one million deaths worldwide annually.
Wed, 02 Apr 2008 05:00:00 PDT - Smokers With Lung Disease Need More Than 'Brief' Intervention
OHSU Smoking Cessation Center researchers outline key steps for developing and implementing clinic-based systems to provide smoking cessation treatment tailored to smokers with respiratory disordersSmokers with lung disease require more than brief smoking cessation interventions to successfully quit, researchers in the Oregon Health & Science University Smoking Cessation Center report.
Wed, 02 Apr 2008 03:00:00 PDT - Phase II Results For CDP791 In Non-small Cell Lung Cancer Support Further Clinical Development
UCB announces first results of its phase II exploratory study of CDP791, a specific VEGFR-2/KDR inhibitor, in combination with carboplatin and paclitaxel chemotherapy in first line non-small cell lung cancer (NSCLC). Positive improvements were observed on several efficacy endpoints including tumour response rate and time to tumour progression. The data support further late stage clinical development of the drug in first line NSCLC.
Mon, 31 Mar 2008 01:00:00 PDT - Fighting Disfiguring Dermatologic Side Effects Of Cancer Treatment
Becky Sasaki has the quick laugh and easy smile of a woman who continues to thrive despite her four-year wrestling match with lung cancer. She still works every day in the family business, heads out for Thai food with her husband and baby sits for her energetic grandchildren.This winter when the cancer, which had metastasized, appeared in her brain for the third time, her oncologist prescribed a new breed of targeted cancer drugs to shrink the tumor.
Fri, 28 Mar 2008 01:00:00 PDT - Amrubicin(R) Receives FDA Orphan Drug Designation For The Treatment Of Small Cell Lung Cancer
Celgene Corporation (NASDAQ: CELG) announced that Amrubicin has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of small cell lung cancer. FDA's Orphan Drug Act was designed to encourage the development of products that demonstrate promise for the diagnosis, prevention and/or treatment of life-threatening or very serious conditions that are rare and affect 200,000 persons or less in the United States.
Thu, 27 Mar 2008 06:00:00 PDT - New Weblog Aims To Raise Awareness Of Deadly Form Of Lung Cancer
Current statistics show 2,000-3,000 people are diagnosed with malignant pleural mesothelioma in the U.S. each year, and 10,000 Americans die from all asbestos-related diseases, according to statistics compiled by the Environmental Working Group. Mesothelioma was not tracked as a specific cause of death by federal health officials until 1999, so actual totals for mesothelioma may be much higher. It is the primary goal of
Thu, 27 Mar 2008 04:00:00 PDT
